Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

Patrick Neven(KU Leuven), George W. Sledge(Caris Life Sciences (United States)), Matthew P. Goetz(Mayo Clinic), Peter A. Kaufman(University of Vermont), Nadine Haddad(Eli Lilly (United States)), Hiroji Iwata(Aichi Cancer Center), Sara M. Tolaney(Harvard University), Karla Hurt(Eli Lilly (United States)), Hope S. Rugo(City of Hope), Masakazu Toi(Mukogawa Women's University), Yi Lu(Shandong Provincial Hospital)
Breast Cancer Research
August 23, 2021
10.1186/s13058-021-01463-2
Cited by 34

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k